Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Altered plasma metabolite levels can be detected years before a glioma diagnosis
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen.ORCID-id: 0000-0001-9228-0625
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi. Biobank Reserach Unit.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: JCI Insight, ISSN 2379-3708, Vol. 8, nr 19, artikel-id e171225Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Genetic and metabolic changes in tissue and blood are reported to occur several years before glioma diagnosis. Since gliomas are currently detected late, a liquid biopsy for early detection could affect the quality of life and prognosis of patients. Here, we present a nested case-control study of 550 prediagnostic glioma cases and 550 healthy controls from the Northern Sweden Health and Disease study (NSHDS) and the European Prospective Investigation into Cancer and Nutrition (EPIC) study. We identified 93 significantly altered metabolites related to glioma development up to 8 years before diagnosis. Out of these metabolites, a panel of 20 selected metabolites showed strong disease correlation and a consistent progression pattern toward diagnosis in both the NSHDS and EPIC cohorts, and they separated future cases from controls independently of biological sex. The blood metabolite panel also successfully separated both lower-grade glioma and glioblastoma cases from controls, up to 8 years before diagnosis in patients within the NSHDS cohort and up to 2 years before diagnosis in EPIC. Pathway enrichment analysis detected metabolites related to the TCA cycle, Warburg effect, gluconeogenesis, and cysteine, pyruvate, and tyrosine metabolism as the most affected.

Ort, förlag, år, upplaga, sidor
American Society For Clinical Investigation, 2023. Vol. 8, nr 19, artikel-id e171225
Nyckelord [en]
Brain cancer, Metabolism, Oncology
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-215372DOI: 10.1172/jci.insight.171225ISI: 001085355700001PubMedID: 37651185Scopus ID: 2-s2.0-85173580693OAI: oai:DiVA.org:umu-215372DiVA, id: diva2:1808405
Forskningsfinansiär
Vetenskapsrådet, 2017-00650Vetenskapsrådet, 2019-01566Cancerfonden, CAN2018/390Cancerfonden, 19 0370Cancerforskningsfonden i Norrland, AMP 21-1045Cancerforskningsfonden i Norrland, AMP22-1084Sjöbergstiftelsen, 2020-01-07-08Folkhälsomyndigheten, 2020-2022World Cancer Research Fund InternationalRegion SkåneRegion VästerbottenTillgänglig från: 2023-10-31 Skapad: 2023-10-31 Senast uppdaterad: 2024-10-02Bibliografiskt granskad
Ingår i avhandling
1. Metabolic signatures in blood for early detection of glioma
Öppna denna publikation i ny flik eller fönster >>Metabolic signatures in blood for early detection of glioma
2024 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Metaboliska signaturer i blod för tidig upptäckt av gliom
Abstract [en]

Glioma is the most common malignant primary brain tumor among adults and is often detected at a late stage of the disease. Treatment often include surgical resection of the tumor followed by combined radiochemotherapy. Yet, the prognosis given to glioma patients is often poor, with the median survival for the most common and aggressive glioma subtype glioblastoma being only 15 months. Due to limited treatment options and poor prognosis, an earlier detection of gliomas could potentially improve the outcome and quality of life for patients. Intriguingly, previous studies have shown that the glioma development may actually start several years before clinical diagnosis is given. In this thesis, a search for altered metabolite levels in blood related to glioma development was conducted, to find biomarkers that show potential to be targets in an early detection tool of glioma and to improve the understanding of the mechanism of the disease.

In Paper I, pre-diagnostic metabolite levels in blood were analyzed from glioma cases that had been collected several years before they were diagnosed together with matched controls. A panel of 20 metabolites were discovered that could predict glioma development up to 8 years before diagnosis in the discovery cohort and up to 2 years before diagnosis in the validation cohort. The altered metabolites showed indication of an altered energy metabolism and imbalanced redox homeostasis.

In Paper II, the altered metabolite levels within 8 years to glioma diagnosis related to an altered energy metabolism was replicated. Longitudinal blood metabolite analysis from years before diagnosis to the time of surgery revealed an altered amino acid metabolism. A set of metabolites with diagnostic potential at surgery and years before diagnosis was presented.

In Paper III, a discovery analysis was conducted on altered metabolite levels at the time of glioma surgery compared to years before diagnosis. A large set of metabolites was significantly altered at surgery, with several metabolic pathways altered including the amino acid metabolism. The pre-diagnostic 20-metabolite panel discovered in Paper I was revisited and their levels were analyzed at surgery, where 8 metabolites showed further significantly elevated levels at surgery as compared to years before, indicating early detection and diagnostic potential for those metabolites.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2024. s. 67
Nyckelord
Glioma, glioblastoma, liquid biopsy, blood, metabolites, early detection, surgery, N-lactoyl-amino-acids, N-lactoyl-phenylalanine
Nationell ämneskategori
Cancer och onkologi Analytisk kemi Bioinformatik (beräkningsbiologi)
Identifikatorer
urn:nbn:se:umu:diva-230465 (URN)9789180705011 (ISBN)9789180705028 (ISBN)
Disputation
2024-11-08, Stora hörsalen (KBE303), KBC-huset, Linnaeus väg 6, Umeå, 09:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2024-10-11 Skapad: 2024-10-01 Senast uppdaterad: 2024-10-02Bibliografiskt granskad

Open Access i DiVA

fulltext(11674 kB)83 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 11674 kBChecksumma SHA-512
8a914ea28493f83219f930799f75b2c01248d774ca6b083a2f67128cfa5d23b1c0bab71ec1675a9eacb2d0ec2a4f80131d476dabe10f884913dc709e85639e21
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Löding, SebastianAndersson, UlrikaNyberg, LarsAntti, HenrikBjörkblom, BennyMelin, Beatrice S.

Sök vidare i DiVA

Av författaren/redaktören
Löding, SebastianAndersson, UlrikaNyberg, LarsAntti, HenrikBjörkblom, BennyMelin, Beatrice S.
Av organisationen
Kemiska institutionenOnkologiInstitutionen för integrativ medicinsk biologi (IMB)Diagnostisk radiologi
I samma tidskrift
JCI Insight
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 83 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 398 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf